What side effects are associated with this type of intervention?

Educational and supportive interventions for obesity management, such as those involving lifestyle modifications, generally have minimal side effects. These interventions focus on diet, physical activity, and behavioral changes, which can lead to improved health outcomes without significant adverse effects. However, patients may experience initial challenges such as muscle soreness from increased physical activity or gastrointestinal discomfort from dietary changes. Pharmacotherapy for obesity, on the other hand, can have side effects including gastrointestinal issues, increased heart rate, and potential impacts on mental health. It is important for patients to discuss these potential side effects with their healthcare provider to tailor the treatment plan to their individual needs.

What prior FDA approvals exist?

The FDA has approved several drugs for the treatment of obesity, including lorcaserin, phentermine-topiramate (Qsymia), and the combination of naltrexone-bupropion (Contrave). These medications have been developed to aid in weight loss and are often used in conjunction with lifestyle interventions such as diet and exercise. The educational and supportive intervention trial, which combines preceptorships with a virtual learning community, aims to enhance primary care physicians' expertise in managing obesity, potentially incorporating these FDA-approved treatments to improve patient outcomes.

What other types of research exist?

Promising, novel alternatives for obesity patients considering treatment in 2024 include: 1) Telehealth services, which have been shown to reduce dropout rates and improve access to care. 2) Online support forums moderated by healthcare professionals to provide accurate information and peer support. 3) Mobile health applications that offer personalized guidance, track progress, and provide educational resources. 4) Digital Cognitive Behavioral Therapy (CBT) programs to address behavioral aspects of obesity management.

← Back to Search

Obesity Management Training for Obesity (ROGMF-2 Trial)

N/A

Waitlist Available

Led By Marie-France Langlois, MD

Research Sponsored by Université de Sherbrooke

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

History of cancer in the last five years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a program that helps doctors manage obesity better through expert mentorship and online support. It targets obese or overweight patients with conditions like hypertension and diabetes, aiming to improve doctors' skills and confidence in treating these patients.

Who is the study for?

This trial is for patients who have had at least four documented visits in the past two years for conditions like hypertension, type 2 diabetes, or impaired glucose tolerance. It's designed to help primary care physician teams improve their management of obesity.

What is being tested?

The study tests an integrated obesity management system that includes a short training program (preceptorship) and ongoing support through a virtual community. The goal is to see if this improves weight loss and obesity care among patients with certain chronic diseases.

What are the potential side effects?

Since this trial focuses on education and support systems rather than medication or medical procedures, there are no direct side effects from interventions being studied.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had cancer within the last five years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: PreceptorshipsExperimental Treatment1 Intervention

Preceptorships with e-learning

Group II: ControlActive Control1 Intervention

No intervention

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for obesity, particularly those involving educational and supportive interventions like the Preceptorship and Virtual Learning Community trial, focus on lifestyle modifications. These include dietary changes to reduce caloric intake, increased physical activity to boost energy expenditure, and behavioral therapy to modify habits contributing to weight gain. These mechanisms are essential for obesity patients as they tackle the underlying causes of obesity, support sustainable weight loss, and enhance overall health and well-being.